Coherus to Acquire Surface Oncology | MarketScreener : compa

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing... | June 16, 2023

Related Keywords

United States , Canada , Cambridge , Cambridgeshire , United Kingdom , China , Coherus Biosciences , Junshi Biosciences , Scott Young , Klinge Pharma , Denny Lanfear , Jodi Sievers , Marek Ciszewski , Rob Ross , Coherus Biosciences Inc , Securities Exchange , Wedbush Securities Inc , Vp Corporate Communications , Latham Watkins , Novartis , Goodwin Procter , Surface Oncology Inc , Drug Administration , Investor Relations Corporate Communications , Nasdaq , Glaxosmithkline , Crimson Merger Subi Inc , Surface Investor Relations Department At Copies , Coheru Investor Relations Department , Arnold Porter Kaye Scholer , Crimson Merger Sub , Coherui O , Surface Oncology , Chief Executive Officer , United States Food , Porter Kaye Scholer , Wedbush Securities , Daylight Time , Biologics License Application , Merger Sub , Securities Act , Securities Exchange Act , Exchange Act , Annual Reports , Quarterly Reports , Registration Statement , Investor Relations Department , General Meeting , Annual Report , Investor Relations , Corporate Communications ,